ORIGINAL RESEARCH

Status of factors of innate immunity in exposed people who subsequently developed cancer

About authors

1 Urals Research Center for Radiation Medicine of the Federal Medical Biological Agency, Chelyabinsk, Russia

2 Chelyabinsk State University, Chelyabinsk, Russia

3 South Ural State Medical University, Chelyabinsk, Russia

Correspondence should be addressed: Eugenia A. Blinova
Vorovsky, 68-А, Chelyabinsk, 454141, Russia; ur.mrcru@avonilb

About paper

Funding: the study was carried out with financial support from the Federal Medical Biological Agency of Russia within the framework of the Federal Target Program “Nuclear and Radiation Safety in 2016-2020 and until 2030” (State Contract № 11.313.21.2 of 15 June 2021).

Author contribution: Blinova EA — synthesis of primary data, analysis and discussion of the results, manuscript writing; Kotikova AI — statistical processing of primary data; Akleyev AA, Akleyev AV — study planning, manuscript editing, preparation of the final version of the article.

Compliance with ethical standards: the study was approved by the Ethics Committee of the Urals Research Center for Radiation Medicine (protocol № 4 of 23 August 2022). All patients submitted the informed consent to study participation.

Received: 2022-08-26 Accepted: 2022-09-14 Published online: 2022-09-29
|
Fig. 1. Linear regression analysis of the dose–response relationships in the group of exposed people who subsequently developed cancer for the following indicators: А — relative eosinophil counts, B — phagocytosis rate of monocytes, C — phagocytic activity of neutrophils
Fig. 2. Linear regression analysis of the dose-dependent decrease in basophil counts for: А — accumulated dose to RBM, B — accumulated dose to thymus and peripheral lymphoid organs
Fig. 3. Linear regression analysis of the dose-dependent increase in the monocyte phagocytic index, comparison group
Table 1. Characteristics of studied groups
Note: n — number of surveyed people; M ± SE — mean ± standard error of the mean; p — significance levels for intergroup differences.
Table 2. Quantity of innate immune cells in blood of examined individuals
Note: Mе (Q1 – Q2 ) — median (25th–75th percentile range).
Table 3. Functional characteristics of innate immune cells in the examined individuals
Note: Mе (Q1 – Q2 ) — median (25th–75th percentile range); ** — significant differences between the studied groups.